Who are PEG -Intron's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Rosiglitazone and Pegasys/Ribavirin, Pegasys(Roche), Peginterferon alfa-2b (PEG).

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/peg-intron.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

PEG -Intron — Competitive Intelligence Brief

PEG -Intron (PEG -Intron) competitive landscape: 3 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Pegylated interferon alfa. Area: Immunology / Virology.

marketed Pegylated interferon alfa Interferon-alpha receptor (IFNAR) Immunology / Virology Small molecule Live · refreshed every 30 min

Target snapshot

PEG -Intron (PEG -Intron) — Beth Israel Deaconess Medical Center. PEG-Intron is a pegylated interferon alfa-2b that enhances and prolongs the antiviral immune response by binding to interferon receptors on immune cells.

Comparator set (3 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
PEG -Intron TARGET	PEG -Intron	Beth Israel Deaconess Medical Center	marketed	Pegylated interferon alfa	Interferon-alpha receptor (IFNAR)
Rosiglitazone and Pegasys/Ribavirin	Rosiglitazone and Pegasys/Ribavirin	Beth Israel Medical Center	marketed	Thiazolidinedione (rosiglitazone) combined with pegylated interferon alfa-2a and nucleoside analog (ribavirin)	PPAR-γ (rosiglitazone); Interferon-α receptor and HCV NS5B polymerase (pegasys/ribavirin)
Pegasys(Roche)	Pegasys(Roche)	Third Affiliated Hospital, Sun Yat-Sen University	phase 3	Pegylated interferon alfa-2a	Interferon alfa receptor (IFNAR)
Peginterferon alfa-2b (PEG)	Peginterferon alfa-2b (PEG)	Merck Sharp & Dohme LLC	phase 3	Pegylated interferon alfa	Interferon-alpha receptor (IFNAR)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Pegylated interferon alfa class)

Beth Israel Deaconess Medical Center · 1 drug in this class
Merck Sharp & Dohme LLC · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). PEG -Intron — Competitive Intelligence Brief. https://druglandscape.com/ci/peg-intron. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab